RUNX3 and acute myeloid leukemia: We found that Runx3 KD significantly ablated AML cells in the peripheral blood (PB) [79.5% reduction on day 28 (d28), 46.9% reduction on d45; Figures 2D, , E] and reduced disease burden in the bone marrow (37.4% reduction on leukemic cell frequency, 47.2% reduction on leukemic cell number; Figure 2F).